株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

避妊薬:パイプライン分析

Contraception - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 279450
出版日 ページ情報 英文 80 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
避妊薬:パイプライン分析 Contraception - Pipeline Review, H2 2015
出版日: 2015年08月12日 ページ情報: 英文 80 Pages
概要

避妊(産児制限)とは、通常の排卵・受精・着床の過程に干渉することで妊娠を防止する手段のことを指します。通常の場合、精子が卵子に到達して受精させるのを防止します。

当レポートでは、世界各国での避妊用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

避妊の概要

避妊関連製品の開発

  • 避妊向けパイプライン製品:概要
  • 避妊向けパイプライン製品:比較分析

各企業で開発中の避妊薬

大学/研究機関で研究中の避妊薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

避妊製品:開発中の製品の一覧(企業別)

避妊製品:研究中の製品の一覧(大学/研究機関別)

避妊薬の開発に従事している企業

  • Antares Pharma, Inc.
  • Actavis plc
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Limited
  • Bayer AG
  • TheraKine Ltd.
  • Ligand Pharmaceuticals, Inc.
  • Intas Pharmaceuticals Ltd.
  • ANI Pharmaceuticals, Inc.
  • HRA Pharma
  • Pantarhei Bioscience BV
  • Hydra Biosciences, Inc.
  • Agile Therapeutics, Inc.
  • Adamis Pharmaceuticals Corporation
  • Evofem, Inc.
  • Evestra, Inc.

避妊:関連製品の評価

  • 単剤治療薬の場合
  • 併用治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • ゲストデン+エチニルエストラジオール
    • 製品概要
    • 機能メカニズム
    • 研究開発(R&D)の進展状況
  • デソゲストレル+エチニルエストラジオール
  • C-31-G
  • 酢酸ノメゲストロール+エストラジオール
  • ノルエチンドロン
  • HRA-081025
  • エチニルエストラジオール+レボノルゲストレル
  • Amphora
  • 酢酸ウリプリスタル
  • デヒドロエピアンドロステロン+エストラジオール+プロゲステロン
  • ネストロン+エストラジオール
  • エストロゲン+プロゲステロン
  • 酢酸ウリプリスタル
  • AG-200 ER
  • エトノゲストレル膣リング
  • レボノルゲストレル
  • HRA-091015
  • 避妊向けCatSper標的小分子
  • タナプロゲト
  • EVE-112
  • EVE-106
  • エストロゲン+プロゲステロン
  • プロゲステロン
  • AGK-10011
  • S-0101255
  • 第二世代のMesoprogestin
  • AG-200 SP

避妊薬:パイプライン製品の最新動向

避妊薬:開発が休止状態の製品

避妊薬:開発が中止された製品

避妊薬関連の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース(全10件)

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC6941IDB

Summary

Global Markets Direct's, 'Contraception - Pipeline Review, H2 2015', provides an overview of the Contraception's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Contraception, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Contraception and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Contraception
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Contraception and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Contraception products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Contraception pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Contraception
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Contraception pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Contraception Overview
  • Therapeutics Development
    • Pipeline Products for Contraception - Overview
    • Pipeline Products for Contraception - Comparative Analysis
  • Contraception - Therapeutics under Development by Companies
  • Contraception - Therapeutics under Investigation by Universities/Institutes
  • Contraception - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Contraception - Products under Development by Companies
  • Contraception - Products under Investigation by Universities/Institutes
  • Contraception - Companies Involved in Therapeutics Development
    • Agile Therapeutics, Inc.
    • Allergan Plc
    • ANI Pharmaceuticals, Inc.
    • Antares Pharma, Inc.
    • Evofem, Inc.
    • Hydra Biosciences, Inc.
    • Ligand Pharmaceuticals, Inc.
    • Orbis Biosciences, Inc.
    • Pantarhei Bioscience BV
    • Spermatech AS
  • Contraception - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (ethinyl estradiol + levonorgestrel) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (nestorone + estradiol acetate) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (prasterone + estradiol + progesterone) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AG-200 ER - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AG-200 SP - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Amphora - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Drug for Male Contraception - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EP-007 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • esterol - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • etonogestrel - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EVE-106 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • levonorgestrel - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • LJ-102 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugates for Contraception - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • norethindrone - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • S-003296 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • S-0101255 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule 1 for Fertility Control - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule 2 for Fertility Control - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Modulate Progesterone Receptor for Fertility Control - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Block CatSper1 Ion Channel for Contraception - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptides for Contraception - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • tanaproget - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Contraception - Recent Pipeline Updates
  • Contraception - Dormant Projects
  • Contraception - Dormant Projects
  • Contraception - Discontinued Products
  • Contraception - Product Development Milestones
    • Featured News & Press Releases
      • Jul 13, 2015: Aquila Solutions,Partners with Evofem to Submit New Drug Application to U.S. FDA for Amphora as a Contraceptive
      • Jul 06, 2015: Evofem Submits New Drug Application to U.S. FDA for Amphora as a Contraceptive
      • Jan 13, 2015: Evofem Announces Pre-NDA Meeting With FDA for Amphora
      • Dec 01, 2014: Agile Therapeutics Announces Publication of Data on Low-Dose Investigational Contraceptive Patch
      • Sep 29, 2014: Agile Announces Dosing of First Patients in Twirla Phase 3 SECURE Study
      • Sep 16, 2014: Agile Initiates Phase 3 SECURE Study for Twirla
      • Jul 17, 2014: Agile Therapeutics Announces Allowance of Additional Patent Claims for Skinfusion
      • Jun 26, 2014: Evofem Announces the Completion of the Largest Phase III Contraceptive Clinical Trial to Date
      • Jun 20, 2014: Agile Therapeutics Announces Issuance of New Patent for Its Skinfusion Transdermal Delivery Device
      • Jul 24, 2013: Health Decisions Completes Enrollment of Evofem's 3,400-subject Global Trial of Amphora Non-hormonal Contraceptive Gel
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Contraception, H2 2015
  • Number of Products under Development for Contraception - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015
  • Contraception - Pipeline by Agile Therapeutics, Inc., H2 2015
  • Contraception - Pipeline by Allergan Plc, H2 2015
  • Contraception - Pipeline by ANI Pharmaceuticals, Inc., H2 2015
  • Contraception - Pipeline by Antares Pharma, Inc., H2 2015
  • Contraception - Pipeline by Evofem, Inc., H2 2015
  • Contraception - Pipeline by Hydra Biosciences, Inc., H2 2015
  • Contraception - Pipeline by Ligand Pharmaceuticals, Inc., H2 2015
  • Contraception - Pipeline by Orbis Biosciences, Inc., H2 2015
  • Contraception - Pipeline by Pantarhei Bioscience BV, H2 2015
  • Contraception - Pipeline by Spermatech AS, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Contraception Therapeutics - Recent Pipeline Updates, H2 2015
  • Contraception - Dormant Projects, H2 2015
  • Contraception - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Contraception, H2 2015
  • Number of Products under Development for Contraception - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Assessment by Combination Products, H2 2015
  • Number of Products by Targets, H2 2015
  • Number of Products by Stage and Targets, H2 2015
  • Number of Products by Mechanism of Actions, H2 2015
  • Number of Products by Stage and Mechanism of Actions, H2 2015
  • Number of Products by Routes of Administration, H2 2015
  • Number of Products by Stage and Routes of Administration, H2 2015
  • Number of Products by Molecule Types, H2 2015
  • Number of Products by Stage and Molecule Types, H2 2015
Back to Top